Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377875 | 0.91 | HRH3 (0.54) | SLC6A4SLC6A2SLC6A3HRH3EPHX2 | |
| SCHEMBL10150946 | 0.88 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HRH3EPHX2 | |
| SCHEMBL19633710 | 0.84 | PDE3B (0.51) | SLC6A4HRH3ADORA2A | |
| SCHEMBL2737409 | 0.83 | HRH3 (0.58) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL22098608 | 0.83 | HRH3 (0.58) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL16217378 | 0.82 | HRH3 (0.47) | SLC6A4HRH3ADORA2A | |
| SCHEMBL15829223 | 0.82 | HRH3 (0.56) | HRH3 | |
| SCHEMBL10262282 | 0.82 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3ADORA2AEPHX2 | |
| SCHEMBL15829993 | 0.82 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3ADORA2AEPHX2 | |
| SCHEMBL10267764 | 0.82 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3ADORA2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3498701-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2935243-B1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | EPIZYME INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9675614-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014100734-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | SLC6A4 4778/4885SLC6A2 4702/4885SLC6A3 4748/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | SLC6A4 4714/4885SLC6A2 4652/4885SLC6A3 4756/4885 |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | SLC6A4 4778/4885SLC6A2 4702/4885SLC6A3 4748/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | SLC6A4 4789/4885SLC6A2 4716/4885SLC6A3 4775/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | SLC6A4 4316/4885SLC6A2 4265/4885SLC6A3 4299/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | SLC6A4 4502/4885SLC6A2 4664/4885SLC6A3 4755/4885 |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | SLC6A4 4386/4885SLC6A2 4350/4885SLC6A3 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.